Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache

ConclusionsPost-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan. Ketorolac exerted its effect without affecting PACAP38-induced arterial dilation, whereas sumatriptan post-treatment attenuated PACAP38-induced dilation of MMA and STA. Pre-treatment with sumatriptan attenuated PACAP38-induced headache without affecting PACAP38-induced arterial dilation. Our findings suggest that ketorolac and sumatriptan attenuated PACAP38-induced headache in healthy volunteers without vascular effects.Trial registrationClinicaltrials.gov (NCT03585894). Registered 13 July 2018,
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research